Once- vs twice-daily dosing of asenapine in patients with a psychotic exacerbation of schizophrenia or schizoaffective disorder

Trial Profile

Once- vs twice-daily dosing of asenapine in patients with a psychotic exacerbation of schizophrenia or schizoaffective disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2013

At a glance

  • Drugs Asenapine (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2013 New trial record
    • 22 May 2013 Results presented at the 166th Annual Meeting of the American Psychiatric Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top